Adel Kardosh, M.D., Ph.D.

Adel Kardosh, M.D., Ph.D., is an Assistant Professor of Medicine in the Division of Hematology/Medical Oncology at Oregon Health & Science University. His research focuses on pancreatic cancer biology, tumor immunology, and immunotherapy resistance, with particular emphasis on spatial proteomics, KRAS-MEK pathway resistance mechanisms, and clonal T cell responses in disease recurrence. He leads the NeoOPTIMIZE phase II trial investigating adaptive neoadjuvant therapy switching for pancreatic adenocarcinoma. His recent work in Nature Cancer and Cancer Research Communications explores androgen receptor activity and immune infiltration across tumor types. He also investigates CD47-targeted therapies for colorectal cancer and advanced solid malignancies.